Search
Displaying 191–200 of 556 for “Retinitis pigmentosa”
-
ARVO 2025 Highlight: J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
Research NewsDespite missing the primary endpoint, the treatment improved vision for some patients.
-
Research News
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
-
Research News
The company is currently enrolling patients in its Phase 2/3 VISTA Clinical Trial.
-
Foundation News
The Foundation Fighting Blindness develops strategic partnership with Alma, a network of 25,000 mental health professionals dedicated to simplifying access to high-quality, affordable mental healthcare.
-
Foundation News
The partnership will formalize an ongoing commitment by both companies to accelerate the development of treatments and cures for retinal diseases, while prioritizing a patient-centric approach.
-
Eye on the Cure Podcast | Episode 83: Michel Michaelides
Eye on the CureProfessor Michaelides talks about the extraordinary vision improvements for young blind children receiving gene therapy for LCA4
-
Honoring the Legacy of Bob Reintsma: A Visionary in the Fight Against Blinding Diseases
Foundation NewsBob Reintsma was fiercely passionate about driving treatments and cures for blinding diseases for most of his life. The Foundation is extremely grateful for Bob’s dedication to our mission and legacy of generosity.
-
Foundation News
With nearly two decades of leadership in vision and neuroscience research and a committed tenure with the Foundation, Dr. Laster will spearhead the Foundation’s scientific strategy in her new role.
-
RD Fund Invests in Perceive Pharma for Development of Neuroprotective Therapies
Research NewsPerceive Pharma is a spin out of Perceive Biotherapeutics.
-
Foundation Fighting Blindness Celebrates 20 Years of VisionWalk
Foundation NewsVisionWalk has been uniting communities across the country for 20 years, all while raising awareness and funding research driving treatments and cures for blinding diseases.
